Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65,833,370
-
Total 13F shares
-
35,559,554
-
Share change
-
+1,068,826
-
Total reported value
-
$1,189,106,240
-
Put/Call ratio
-
114%
-
Price per share
-
$33.44
-
Number of holders
-
127
-
Value change
-
+$60,325,552
-
Number of buys
-
70
-
Number of sells
-
57
Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q2 2021
As of 30 Jun 2021,
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,559,554 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Redmile Group, LLC, BlackRock Inc., EVENTIDE ASSET MANAGEMENT, LLC, STATE STREET CORP, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, ADAGE CAPITAL PARTNERS GP, L.L.C., VR Adviser, LLC, and ACUTA CAPITAL PARTNERS, LLC.
This page lists
127
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.